Thrive Capital Partners VII Growth, L.P.'s Form 4 filing
Oscar Health, Inc. (OSCR) · filed Sep 1, 2021
- Accession no.
- 0000899243-21-034820
- Filed
- Sep 1, 2021, 7:56 PM ET
- Trade date
- Aug 30-31, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $9.53M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thrive Capital Partners VII Growth, L.P.CIK 0001841736 | 10% Owner |
| Claremount VII Associates, L.P.CIK 0001841808 | 10% Owner |
| Thrive Partners VII GP, LLCCIK 0001877733 | 10% Owner |
| Thrive Partners VII Growth GP, LLCCIK 0001877735 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 30, 2021 | Class A Common Stock | PPurchaseAcquired | +274,697 | $14.68F1 | +$4,033,760.63 | 1,997,676 | Indirect | |
| Aug 30, 2021 | Class A Common Stock | PPurchaseAcquired | +55,188 | $15.27F3 | +$842,770.43 | 2,052,864 | Indirect | |
| Aug 31, 2021 | Class A Common Stock | PPurchaseAcquired | +93,836 | $14.81F4 | +$1,389,861.3 | 2,146,700 | Indirect | |
| Aug 31, 2021 | Class A Common Stock | PPurchaseAcquired | +211,703 | $15.43F5 | +$3,267,170.06 | 2,358,403 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F3
Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F4
Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.
- F5
Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII.
Referenced by the price of 1 transaction in Table I.